European Medicines Data Standards Offer Business Opportunities For Life Science Firms
Executive Summary
The newly published EU IDMP guide on implementing ISO data standards for the identification of medicinal products will keep regulatory affairs professionals busy with compliance work while also creating new data-driven opportunities for life sciences companies. Remco Munnik shares the inside track from his work with the EU focus group that created the guide.
You may also be interested in...
UK Imposes New Limits On Deferring Registration Of Clinical Trials
The UK is changing its policy for deferring the registration of a clinical trial on grounds of commercial sensitivity, and is introducing updated guidance on the minimum information that sponsors of such studies should still make public.
EU Bans Titanium Dioxide In Supplements, Drugs Given Reprieve, For Now
Titanium dioxide is now officially banned as an ingredient in foods and dietary supplements in the European Union on safety grounds. However, manufacturers can still place products containing the chemical compound on the market for six months, and then any products still on the market can remain until their expiry date. Meanwhile, the European Commission and pharmaceutical companies have three years to find titanium dioxide alternatives for medicines, or justify why it should continue to be used.
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.